Work

GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz247.162

Authors: M. Shah, J.A. Ajani, S.-E. Al-Batran, Y.-J. Bang, D.V. Catenacci, P. Enzinger, D. Ilson, S. Kim, F. Lordick, K. Shitara, E. Van Cutsem, A. Arozullah, J.W. Park, R.-H. Xu

Institutions: Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Krankenhaus Nordwest, Seoul National University, Seoul National University Hospital, University of Chicago, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Georgetown University Medical Center, MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center, University Hospital Leipzig, Leipzig University, National Cancer Center Hospital East, KU Leuven, Astellas Pharma (United States), Sun Yat-sen University, Sun Yat-sen University Cancer Center

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2977499594

FWCI: 0.736

Cites:

Cited by: 8

Related to: 10